L&C Bio reports net loss of 129 billion won in 2025
L&C Bio reported a net loss of 129 billion won in 2025, despite revenue growth. The loss was attributed to non-cash factors like derivative valuation losses.
Namutech signed a contract with GMRC to supply NAA, an AI-based solution for automating clinical trial reports, improving research efficiency and providing multilingual translation.
Humedics to acquire 223,214 shares of L&C Bio through a capital increase, strengthening aesthetic business cooperation. The acquisition cost is 14.99 billion won.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.